30th week of 2009 patent applcation highlights part 36 |
Patent application number | Title | Published |
20090186791 | Skin External Preparation - The present invention is to provide a new surfactant that can be used as an emulsifier excellent in emulsion stability and texture in use and as a cleanser excellent in cleansing power and texture in use and having low skin irritation. A surfactant consisting of a compound represented by the below-described general formula (1). | 2009-07-23 |
20090186792 | GEL COSMETIC COMPOSITION - There is provided a cosmetic composition, which stably includes disintegrable particles and is excellent in feeling upon use. A gel cosmetic composition, which has a pH of 4 to 9 and includes the following components (A), (B), (C), (D), and (E):
| 2009-07-23 |
20090186793 | DYNAMIC MULTI-PURPOSE COMPOSITION FOR THE REMOVAL OF PHOTORESISTS AND METHOD FOR ITS USE - Improved dry stripper solutions for removing one, two or more photoresist layers from substrates are provided. The stripper solutions comprise dimethyl sulfoxide, a quaternary ammonium hydroxide, and an alkanolamine, an optional secondary solvent and less than about 3 wt. % water and/or a dryness coefficient of at least about 1. Methods for the preparation and use of the improved dry stripping solutions are additionally provided. | 2009-07-23 |
20090186794 | DETERGENT COMPOSITION COMPRISING A BLOCK COPOLYMER - The invention relates to a detergent composition, suitable for use in dish washing or laundry, comprising at least 15% of a detersive surfactant(s), and a block copolymer, selected from the group consisting of (block A)-(block B) diblock copolymers, (block A)-(block B)-(block A) triblock copolymers, and (block B)-(block A)-(block B) triblock copolymers, wherein block A and block B derive from alpha ethylenically unsaturated monomers, at least one block being water-soluble. The detergent compositions provide an increased cleaning, and/or a decreased redeposition of the fatty substances once they are removed from a substrate. | 2009-07-23 |
20090186795 | Automatic Phosphate-Free Dishwashing Detergent Providing Improved Spotting and Filming Performance - A phosphate free automatic dishwashing detergent provides improved spotting and filming performance by including a spot reduction system that contains a combination of a polyacrylate and a carboxymethyl inulin. The detergent also includes an enzyme system that contains a combination of Esperase® 6.0T and an alkaline stable protease. | 2009-07-23 |
20090186796 | LIQUID DETERGENT COMPOSITION - The present invention relates to a light duty liquid detergent composition comprising a low molecular weight hydrophobically modified cellulosic polymer, to provide improved foaming properties. | 2009-07-23 |
20090186797 | LAUNDRY COMPOSITION - According to the present invention there is provided a laundry detergent composition, comprising a hueing dye and a pearlescent agent, wherein the hueing dye exhibits a hueing efficiency of at least 10 and a wash removal value in the range of from about 30% to about 85%. | 2009-07-23 |
20090186798 | Colour-Care Composition - Composition with improved fabric and colour care benefits. The composition comprises dye transfer inhibitor(s) and a silicone. The compositions are suitable for use in laundry treatment processes for improving the colour vibrancy of the fabrics. | 2009-07-23 |
20090186799 | TERNARY AZEOTROPIC-LIKE COMPOSITIONS WITH 1,1,1,2,3,3-HEXAFLUORO-3-METHOXY-PROPANE AND TRANS-1,2-DICHLOROETHYLENE - Ternary azeotrope and azeotrope-like compositions containing 1,1,1,2,3,3-hexafluoro-3-methoxy-propane, trans-1,2-dichloroethylene and a third component, and methods of using azeotropes and azeotrope-like compositions to clean substrates, deposit coatings, transfer thermal energy, and lubricate working operations are described. | 2009-07-23 |
20090186800 | TERNARY AZEOTROPIC-LIKE COMPOSITIONS WITH 1,1,1,2,3,3-HEXAFLUORO-3-METHOXY-PROPANE AND 1-BROMOPROPANE - Ternary azeotrope and azeotrope-like compositions containing 1,1,1,2,3,3-hexafluoro-3-methoxy-propane, 1-bromopropane and a third component, and uses thereof, are described. | 2009-07-23 |
20090186801 | Methods of Inhibiting Tumor Cell Aggressiveness Using The Microenvironment of Human Embryonic Stem Cells - The invention provides compositions comprising one or more isolated factors from a microenvironment of human embryonic stem cells (hESCs), including, but not limited to, Lefty and inhibitors of Nodal. The invention also provides methods of utilizing factors derived from human embryonic stem cells (hESC) and their microenvironment to treat and prevent tumor formation and progression and to inhibit tumor cell aggressiveness. The invention further provides methods of inhibiting tumor cell growth and/or treating aggressive tumors in a mammal comprising administering to the mammal, having at least one tumor cell present in its body, an effective amount of an inhibitor of Nodal activity. | 2009-07-23 |
20090186802 | Cell Penetrating Peptide Conjugates for Delivering of Nucleic Acids into a Cell - The invention provides cell penetrating peptide-nucleic acid conjugates having the formula P-L-N, wherein P is a cell penetrating peptide, N is a nucleic acid, preferably an oligonucleotide and more preferably a siRNA, and L is a hydrophilic polymer, preferably a polyethylene glycol (PEG)-based linker linking P and N together. Compositions, methods of use and methods for producing such conjugates are also disclosed. | 2009-07-23 |
20090186803 | USE OF NUTRITIONAL COMPOSITIONS WITH PHOSPHOLIPID, SPHINGOLIPID AND CHOLESTEROL. - A nutritional composition comprising phospholipids, sphingolipids and cholesterol for the prevention of obesity and/or diabetes is provided. | 2009-07-23 |
20090186804 | ANTICOAGULANT AND COMPOSITION FOR PREVENTING THROMBUS CONTAINING POLY-GAMMA-GLUTAMIC ACID - The present invention relates to an anticoagulant and a composition for preventing thrombus formation, which contain poly-gamma-glutamic acid (PGA) as an active ingredient. The inventive PGA is a water-soluble, anionic, biodegradable and edible amino acid polymer material, which has an anticoagulant effect of preventing thrombi from being accumulated in blood vessels, shows an excellent sustained-release effect and is harmless to the human body. Thus, it is useful as a high-value-added anticoagulant and a food or beverage composition for preventing thrombus formation. | 2009-07-23 |
20090186805 | Compositions and Methods for Genetic Modification of Cells Having Cosmetic Function to Enhance Cosmetic Appearance - Disclosed are methods and compositions to genetically modify substantially intact cells having cosmetic function to enhance the cosmetic appearance in mammals so as to enhance and/or maintain a biochemical and/or physiological process that has a positive effect on cosmetic appearance. The methods and compositions may provide cosmetic benefits such as reduced skin sagging, increased skin thickness, reduced wrinkles, increased skin thickness and collagen content, increased skin tone and elasticity, increased skin hydration, and improved skin texture and color. | 2009-07-23 |
20090186806 | Truncated Activin Type II Receptor and Methods of Use - The present invention provides a substantially purified growth differentiation factor (GDF) receptor, including a GDF-8 (myostatin) receptor, as well as functional peptide portions thereof. In addition, the invention provides a virtual representation of a GDF receptor or a functional peptide portion thereof. The present invention also provides a method of modulating an effect of myostatin on a cell by contacting the cell with an agent that affects myostatin signal transduction in the cell. In addition, the invention provides a method of ameliorating the severity of a pathologic condition, which is characterized, at least in part, by an abnormal amount, development or metabolic activity of muscle or adipose tissue in a subject, by modulating myostatin signal transduction in a muscle cell or an adipose tissue cell in the subject. The invention also provides a method of modulating the growth of muscle tissue or adipose tissue in a eukaryotic organism by administering an agent that affects myostatin signal transduction to the organism. | 2009-07-23 |
20090186807 | Zinc-free and low-zinc insulin preparations having improved stability - The invention relates to a formulation comprising a polypeptide selected from at least one of insulin, an insulin metabolite, an insulin analog, and an insulin derivative; at least one surfactant; optionally at least one preservative; and optionally at least one of an isotonicizing agent, a buffer or an excipient, wherein the formulation is free from or low in zinc. The invention also relates to the production of such insulin preparations and their use as pharmaceutical formulations. | 2009-07-23 |
20090186808 | Method and Compound for the Treatment of Valvular Disease - A method for treating valvular stenosis The method involves the administration of a therapeutically effective amount of a reverse lipid (in particular cholesterol) transport agonist to a mammal Most preferred is an Apolipoprotein A-1 mimetic peptide/phospholipid complex, the peptide of which is defined by the amino acid sequence of SEQ ID NO 1. | 2009-07-23 |
20090186809 | USE OF VALPROIC ACID FOR THE TOPICAL TREATMENT OF MILD TO MODERATE ACNE VULGARIS - The present invention provides a surprising therapeutic beneficial use for the topical application of valproic acid as a single agent therapy for patients suffering from mild to moderate acne vulgaris. Topically applied VPA has a clinical efficacy comparable to that of the marketed standard medication for this indication, isotretinoin. Furthermore, topically applied VPA is on average well to very well tolerated. The invention relates to the topical medical use of VPA for the treatment of acne vulgaris and comprises the topical application of VPA or of a pharmaceutically acceptable salt thereof. | 2009-07-23 |
20090186810 | POTASSIUM CHANNEL MODULATORS AND PLATELET PROCOAGULANT ACTIVITY - Methods of modulating platelet procoagulant response are taught herein. Inhibition of platelet procoagulant response with agents that inhibit the Ca | 2009-07-23 |
20090186811 | Y2 Selective Receptor Agonists for Therapeutic Interventions - Y receptor agonists other than PYY 3-36, which are selective for the Y2 receptor over the Y1 and Y4 receptors, and their use in the treatment of conditions responsive to activation of Y2 receptors, are disclosed. Broadly, a Y2-selective agonist is one which (a) is a PP-fold peptide or PP-fold peptide mimic selected from PYY, NPY, PYY mimics and NPY mimics which have a C-terminal Y2 receptor-recognition amino acid sequence and have various modifications relative to the natural peptides or (b) a PP-fold peptide or PP-fold peptide mimic selected from PP and PP-mimics which have a C-terminal Y2 receptor-recognition amino acid sequence and which have various modifications relative to the natural peptide or (c) comprise a C-terminal Y2 receptor-recognition amino acid sequence fused at its N-terminus to an amphiphilic amino acid sequence domain comprising at least one alpha helical turn adjacent the N-terminus of the said Y2 receptor-recognition sequence, said turn being constrained in a helical configuration by a covalent intramolecular link, and (ii), in the case where the agonist has an N-terminal structure analogous to NPY or PYY, having one or more of the modifications listed in (a) above and, in the case where the agonist has an N-terminal structure analogous to PP, having one or more of the modifications listed in (b) above. | 2009-07-23 |
20090186812 | Apo-2 ligand - A novel cytokine, designated Apo-2 ligand, which induces mammalian cell apoptosis is provided. The Apo-2 ligand is believed to be a member of the TNF cytokine family. Compositions including Apo-2 ligand chimeras, nucleic acid encoding Apo-2 ligand, and antibodies to Apo-2 ligand are also provided. Methods of using Apo-2 ligand to induce apoptosis and to treat pathological conditions such as cancer, are further provided. | 2009-07-23 |
20090186813 | CHRONIC TREATMENT REGIMEN USING GLUCAGON-LIKE INSULINOTROPIC PEPTIDES - The present invention encompasses a method of treating a disease by maintaining chronic steady state serum levels of a GLP-1 compound within a specified range. | 2009-07-23 |
20090186814 | Methods and Compositions for Reducing Ischemia-Derived Microvascular Damage - Methods of decreasing the extent of occlusion in the lumen of a mammalian blood vessel due to an ischemic or other hypoxic event are provided. In one form, a method includes administering to a patient in need thereof a pharmaceutically effective amount of an inhibitor of δ protein kinase C, either alone or in combination with a second therapeutic agent, and wherein the blood vessel is a blood vessel of the microvasculature. Additionally, methods of decreasing endothelial cell swelling in a mammalian blood vessel due to an ischemic or other hypoxic event are also provided. In one form, a method includes administering to a patient in need thereof a pharmaceutically effective amount of an inhibitor of δ protein kinase C, either alone or in combination with a second therapeutic agent. | 2009-07-23 |
20090186815 | IDENTIFICATION OF JAK/STAT PATHWAY MODULATING GENES BY GENOME WIDE RNAI SCREENING - The present invention relates to a method for identifying a compound capable of modulating the activity of the JAK/STAT pathway and to the use of different JAK/STAT pathway components as a target for the modulation of the activity of the JAK/STAT pathway. Moreover, the present invention is concerned with a method for modulating the activity of the JAK/STAT pathway. Furthermore, the present invention pertains to a pharmaceutical composition and to the use of different JAK/STAT pathway components and/or effector molecules thereof for the manufacture of such composition for the diagnosis, prevention or treatment of a JAK/STAT pathway associated disorder. | 2009-07-23 |
20090186816 | POLYPEPTIDE TARGETING TO MITOCHONDRIA - Methods for delivering non-mitochondrial proteins to mitochondria are provided. Also provided are nucleic acid constructs comprising a coding sequence encoding a DNA-binding polypeptide, fused to a mitochondrial targeting sequence (MTS) and a nuclear export signal (NES), and the encoded proteins. The construct successfully delivers DNA binding proteins to the mitochondrion. A chimeric methylase based on the above construct is successfully delivered to mitochondria, resulting in modification of mtDNA. | 2009-07-23 |
20090186817 | PEPTIDE-PEPTIDASE INHIBITOR CONJUGATES AND METHODS OF USING SAME - Peptide-peptidase inhibitor conjugate molecules are disclosed. These conjugate molecules are useful as agents for the treatment and prevention of metabolic and cardiovascular diseases, disorders, and conditions. Such diseases, conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, and other diabetes-related disorders. | 2009-07-23 |
20090186818 | Therapeutic Method for Glycaemic Control - The invention relates to a therapeutic method for glycaemic control, comprising the use of a combination of a DPIV inhibitor and a GLP-1 receptor agonist. | 2009-07-23 |
20090186819 | FORMULATION OF INSULINOTROPIC PEPTIDE CONJUGATES - The present invention provides pharmaceutical formulations comprising insulinotropic peptide conjugates, particularly a conjugate of albumin to exendin-4, or a derivative thereof, and methods of administration thereof. The present invention also provides methods for treating diabetes and insulinotropic peptides related diseases or conditions by administering the pharmaceutical formulations described herein. | 2009-07-23 |
20090186820 | STREPTOCOCCUS PYOGENES POLYPEPTIDES AND CORRESPONDING DNA FRAGMENTS - The present invention relates to antigens, more particularly antigens of | 2009-07-23 |
20090186821 | USE OF ASPARTIC PROTEASES IN COSMETICS AND THERAPEUTICS - The invention provides a cosmetic or pharmaceutical composition comprising, in a physiologically acceptable medium, at least one purified natural or synthetic polypeptide wherein the peptide sequence is represented wholly or partly by at least one sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 16, SEQ ID NO: 25 and SEQ ID NO: 27 and their homologs. | 2009-07-23 |
20090186822 | Thrombopoietic Compounds - The invention relates to the field of compounds, especially peptides or polypeptides, that have thrombopoietic activity. The peptides and polypeptides of the invention may be used to increase platelets or platelet precursors (e.g., megakaryocytes) in a mammal. | 2009-07-23 |
20090186823 | Synthetic arginine substituted peptides and their use - The present invention relates to new arginine substituted peptides designed based on the sequence of human lactoferrin and to use thereof, in particular for treatment and/or prevention of infections, inflammations, tumours, pain, wounds and/or scars. | 2009-07-23 |
20090186824 | NOVEL PEPTIDES FOR TREATING AND PREVENTING IMMUNE-RELATED DISORDERS, INCLUDING TREATING AND PREVENTING INFECTION BY MODULATING INNATE IMMUNITY - In one aspect, the present invention provides isolated novel peptides that can be used to modulate innate immunity in a subject and/or for the treatment of an immune-related disorder, including treating and preventing infection by modulating innate immunity. Also provided are an agent reactive with the peptide, a pharmaceutical composition that includes the peptide, an isolated nucleic acid molecule encoding the peptide, a recombinant nucleic acid construct that includes the nucleic acid molecule, at least one host cell comprising the recombinant nucleic acid construct, and a method of producing the peptide using the host cell. The present invention further provides a method for treating and/or preventing infection in a subject by administering the peptide of the invention to the subject, thereby modulating innate immunity in the subject. Additionally, the present invention provides a method for predicting whether a subject would be responsive to treatment with a peptide of the invention. | 2009-07-23 |
20090186826 | Cosmetic or dermopharmaceutical compositions of ceramides and polypeptides - Personal care products including cosmetics, grooming products and topical pharmaceutical products can be produced including a polypeptide of between 3 and 12 amino acids in length and a ceramide. These formulations are particularly useful in addressing wrinkles in human subjects and in particular facial skin and hands. Certain analogs and derivatives of these polypeptides may be used in these formulations and/or alone. Methods of using these formulations are also disclosed. | 2009-07-23 |
20090186827 | Process of inhibiting cell death in injured cartilage - Processes for inhibiting apoptotic cell death and glycosaminoglycan release from injured cartilage is provided. Inhibition is accomplished using caspase inhibitors. | 2009-07-23 |
20090186829 | Nitrosation-Inducible Inhibitors Biological Macromolecules - Biomacromolecules such as proteins are inactivated by hydrophobic ANSA derivatives of the formula: | 2009-07-23 |
20090186830 | MACROCYCLES AND THEIR USES - The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of diseases. | 2009-07-23 |
20090186831 | Tetrahydrofuro(3,2-B) pyrrol-3-one derivatives as inhibitors of cysteine proteinases - A compound of formula (I), or a pharmaceutically acceptable salt, hydrate, complex or pro-drug thereof, | 2009-07-23 |
20090186832 | AMINO ACID PEPTIDE PRO-DRUGS OF PHENOLIC ANALGESICS AND USES THEREOF - Prodrugs of meptazinol and other phenolic analgesics exhibiting low oral bioavailability with amino acids or lower peptides, pharmaceutical compositions containing such prodrugs and a method for providing pain relief with such prodrugs are provided. In addition, the present invention relates to methods for increasing the oral bioavailability of a phenolic analgesic. The method comprises orally administering a phenolic analgesic prodrug, wherein the phenolic analgesic is bound to an amino acid or peptide via a carbamate linkage, to a subject in need thereof. Prodrugs having side chains of valine, leucine, isoleucine and glycine amino acids and mono-, di- and tripeptides thereof are preferred. | 2009-07-23 |
20090186833 | METHOD FOR PRODUCING PECTIN HYDROLYSIS PRODUCTS - Methods for the production of pectin hydrolysis products, the pectin hydrolysis products produced in this manner, as well as their use are described. | 2009-07-23 |
20090186834 | DIPHENYLHETEROCYCLE CHOLESTEROL ABSORPTION INHIBITORS - Various azetidinone, pyrrolidine, imidazolidine, and oxazolidine derivatives are described, as are pharmaceutical compositions containing these compounds and methods of treatment of diseases using these compounds. Other embodiments are also described. | 2009-07-23 |
20090186835 | TREATMENT AND PROPHYLAXIS OF CANCER - A method and composition for the prophylaxis or treatment of humans or animals for cancer using a mixture of sophorolipids. | 2009-07-23 |
20090186836 | METHOD FOR NEUTRALIZING FUNGI USING SOPHOROLIPIDS AND ANTIFUNGAL SOPHOROLIPIDS FOR USE THEREIN - 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octa-decenoate, lactonic and open ring 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate, methyl 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate, ethyl 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate, hexyl 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate, ethyl 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate-6″-acetate and ethyl 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate-6′,6″-diacetate sophorolipids and uses thereof as antifungal agents. | 2009-07-23 |
20090186837 | Anti-neoplastic compositions comprising extracts of black cohosh - A method for treating, preventing or ameliorating breast cancer is provided by administering a synergistic amount of digitoxin and either actein or an extract of black cohosh comprising triterpene glycosides, and optionally another chemopreventive agent which may be paclitaxel. Methods for treating or preventing a neoplasia using a synergistic combination, and compositions of a synergistic combination of a cardiac glycoside and either actein or an extract of black cohosh comprising triterpene glycosides, and optionally another chemopreventive agent which may be a taxane are also provided. The compositions may also be used in a method for modulating Na | 2009-07-23 |
20090186838 | Amphotericin Derivatives - The present invention provides new polyene macrolide derivatives which show very low toxicity while retaining high antifungal activity as compared with amphotericin B (AmB). These polyene macrolide derivatives comprise a polyene macrolide backbone having at least one free amino group, wherein the amino group is doubly alkylated with at least one hydrocarbon group carrying a total of at least two basic groups. | 2009-07-23 |
20090186839 | Model for studying the role of genes in chemoresistance - The invention provides novel inhibitors of protein translation initiation and inhibitors of eIF4F activity that can increase chemosensitivity or diminish or reverse chemoresistance in growth transformed cells and thereby reduce hyperproliferative conditions, such as cancer progression, in select patient populations having particular tumor genotypes. The invention also provides methods which target translation initiation controls in growth-transformed cells, such as tumor subtypes with altered expression of a gene activity, including the human akt, bcl-2, eIF4E, eIF4A or PTEN activities, to restore drug sensitivity in vivo in a genotype selective manner. In one aspect, the inhibitors of translation initiation of the invention are rocaglates, i.e., cyclopenta[b]benzofurons, which increases chemosensitivity or diminishes or reverses chemoresistance either alone or in combination, additively or synergistically, with other agents that alter growth or death. Preferably, the rocaglate is silvestrol, which is used alone or in combination with doxorubicin to reverses chemoresistance in PTEN-deficient lymphomas or eIF4E-over-expressing lymphomas and to promote cancer remission. | 2009-07-23 |
20090186840 | 5-Thioxylopyranose Compounds - Compounds of 5-thioxylopyranose, preferably derivatives of the 5-thioxilopyranose type, a method for preparing such compounds, and the use of such compounds as an active ingredient in pharmaceutical compositions which are useful, in particular, for treating or inhibiting thrombosis or heart failure or thromboembolic disease states. | 2009-07-23 |
20090186841 | Novel aminoglycoside antibiotics - This invention relates to novel aminoglycoside antibiotics, which have potent antimicrobial activity against bacteria, which induce infectious diseases, particularly MRSA, and has no significant nephrotoxicity, and process for producing them. More particularly, the present invention relates to compounds represented by formula (Ia) or their pharmacologically acceptable salts or solvates, or their diastereomer mixtures, antimicrobial agents comprising them, and a process for producing them. | 2009-07-23 |
20090186842 | Methods and compositions for inhibition of viral replication - The present invention is directed to methods and compositions that are effective in the inhibition of viral replication. In particular, the methods and compositions are effective at interfering with the activity of host cell proteins required in viral replication. For example, an embodiment of the invention is directed to methods and compositions comprising RNA sequences to which the host cell proteins TIAR and/or TIA-1 bind. | 2009-07-23 |
20090186843 | RNA sequence-specific mediators of RNA interference - The present invention relates to a Drosophila in vitro system which was used to demonstrate that dsRNA is processed to RNA segments 21-23 nucleotides (nt) in length. Furthermore, when these 21-23 nt fragments are purified and added back to Drosophila extracts, they mediate RNA interference in the absence of long dsRNA. Thus, these 21-23 nt fragments are the sequence-specific mediators of RNA degradation. A molecular signal, which may be their specific length, must be present in these 21-23 nt fragments to recruit cellular factors involved in RNAi. This present invention encompasses these 21-23 nt fragments and their use for specifically inactivating gene function. The use of these fragments (or chemically synthesized oligonucleotides of the same or similar nature) enables the targeting of specific mRNAs for degradation in mammalian cells, where the use of long dsRNAs to elicit RNAi is usually not practical, presumably because of the deleterious effects of the interferon response. This specific targeting of a particular gene function is useful in functional genomic and therapeutic applications. | 2009-07-23 |
20090186844 | SiRNA DELIVERY INTO MAMMALIAN NERVE CELLS - The present invention relates to methods of affecting expression of a target gene, suitably brain-derived neurotrophic factor (BDNF) or related genes in a nerve cell in the central nervous system of a mammal. The method includes formulating and delivering an siRNA composition to a target site on the mammal to affect expression of the target gene in the nerve cell, wherein the target site is cerebrospinal space or muscle tissue innervated by a nerve cell, to down-regulate the target gene. Also disclosed are kits for use in practicing the novel methods of in vivo siRNA.delivery into target cells and gene regulation. | 2009-07-23 |
20090186845 | INTERFERING RNA MOLECULES - The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended. | 2009-07-23 |
20090186846 | Methods to reprogram splice site selection in pre-messenger RNAs - The present invention relates to a method of modulating splice site selection, splicing and alternative, the method comprising the step of hybridizing an oligonucleotide-protein conjugate to a target pre-mRNA molecule in a cell or cell extract, wherein the oligonucleotide-protein conjugate comprises an oligonucleotide moiety which comprises at least two distinct sequence elements: (i) a nucleic acid sequence that is complementary to a specific region upstream of the splice site in the target pre-mRNA molecule; and (ii) an extension containing a protein binding site sequence element for covalently binding a protein; wherein the protein moiety comprises a protein capable of modulating splicing of the splice site upon binding with the protein binding site. | 2009-07-23 |
20090186847 | ANTISENSE ANTIVIRAL COMPOUNDS AND METHODS FOR TREATING A FILOVIRUS INFECTION - The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Filoviridae family, and in the treatment of a viral infection. The compounds and methods relate to the treatment of viral infections in mammals including primates by Ebola and Marburg viruses. The antisense antiviral compounds are morpholino oligonucleotides having: a) a nuclease resistant backbone, b) 15-40 nucleotide bases, and c) a targeting sequence of at least 15 bases in length that hybridizes to a target region selected from the following: i) the Ebola virus AUG start site region of VP24; ii) the Ebola virus AUG start site region of VP35; iii) the Marburg virus AUG start site region of VP24; or iv) the Marburg virus AUG start site region of NP. | 2009-07-23 |
20090186848 | ANTISENSE ANTIVIRAL COMPOUNDS AND METHODS FOR TREATING A FILOVIRUS INFECTION - The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Filoviridae family, and in the treatment of a viral infection. The compounds and methods relate to the treatment of viral infections in mammals including primates by Ebola and Marburg viruses. The antisense antiviral compounds are morpholino oligonucleotides having: a) a nuclease resistant backbone, b) 15-40 nucleotide bases, and c) a targeting sequence of at least 15 bases in length that hybridizes to a target region selected from the following: i) the Ebola virus AUG start site region of VP24; ii) the Ebola virus AUG start site region of VP35; iii) the Marburg virus AUG start site region of VP24; or iv) the Marburg virus AUG start site region of NP. | 2009-07-23 |
20090186849 | ANTISENSE ANTIVIRAL COMPOUNDS AND METHODS FOR TREATING A FILOVIRUS INFECTION - The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Filoviridae family, and in the treatment of a viral infection. The compounds and methods relate to the treatment of viral infections in mammals including primates by Ebola and Marburg viruses. The antisense antiviral compounds are morpholino oligonucleotides having: a) a nuclease resistant backbone, b) 15-40 nucleotide bases, and c) a targeting sequence of at least 15 bases in length that hybridizes to a target region selected from the following: i) the Ebola virus AUG start site region of VP24; ii) the Ebola virus AUG start site region of VP35; iii) the Marburg virus AUG start site region of VP24; or iv) the Marburg virus AUG start site region of NP. | 2009-07-23 |
20090186850 | PERITONEAL DIALYSIS METHOD - A peritoneal dialysate containing adenosine triphosphate or a salt thereof, and a peritoneal dialysis method using the dialysate. | 2009-07-23 |
20090186851 | HEMOSTATIC MATERIAL - A hemostatic powder comprises a chitosan salt together with at least one inert material. The disclosure also relates to hemostatic powders into which fluid penetrability is 0.5 cm or more within 1 minute. At least one medical surfactant may optionally be included. The hemostatic powders may be incorporated into wound dressings. | 2009-07-23 |
20090186852 | TRI- AND TETRA-OLIGO-SACCHARIDES SUITABLE AS AGGLUTINATION AGENTS FOR ENTERIC PATHOGENS - Compositions which include a homotrimer, heterotrimer, homotetramer, and/or heterotetramer of a component such as pentose, hexose, an L or D isomer of a pentose or hexose, a β-form of a pentose or hexose, oxidized derivatives and mixtures of such compounds are disclosed as agglutination agents. The disclosed compositions are useful for agglutination of enteric pathogens and may be used for selectively controlling and regulating the microbial ecosystem in the gastrointestinal tract of a subject. | 2009-07-23 |
20090186853 | COMPOSITIONS COMPRISING N-PROPANOYL DERIVATIVES OF AMINO ACIDS, AMINOCARBOHYDRATES AND DERIVATIVES THEREOF - The embodiments relate to compositions comprising therapeutically effective amounts of at least one N-propanoyl derivative of amino acids, aminocarbohydrates, and derivatives thereof. The compositions are useful the prevention and treatment of symptoms or syndromes associated with nervous, vascular, musculoskeletal, or cutaneous systems. The compositions may be topically or systemically administered to a subject in need thereof. | 2009-07-23 |
20090186854 | S-ALKYLISOTHIOURONIUM DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES - The present invention relates to uses of S-alkylisothiouronium derivatives for treating inflammation. In particular, the present invention provides extended release pharmaceutical dosage forms of S-alkylisothiouronium derivatives and methods of use thereof for the treatment of various inflammatory diseases or conditions. | 2009-07-23 |
20090186855 | COMPOUNDS AND METHODS FOR TREATING TOLL-LIKE RECEPTOR 2-RELATED DISEASES AND CONDITIONS - The present invention relates to compounds and methods useful in the prevention or treatment of diseases or conditions associated with Toll-like receptor 2 activation. | 2009-07-23 |
20090186856 | MICRONUTRIENT PHOSPHATES AS DIETARY AND HEALTH SUPPLEMENTS - There is provided a dietary or health supplement comprising an effective amount of a micronutrient selected from the group consisting of phosphate derivatives of tocopherol, ubiquinol, ascorbic acid, tocotrienol, retinol and mixtures thereof delivered with an acceptable carrier. | 2009-07-23 |
20090186857 | Combretastatin A-4 Phosphate Prodrug Mono- and Di- Organic Amine Salts, Mono- and Di- Amino Acid Salts, and Mono- and Di- Amino Acid Ester Salts - Provided herein are novel and useful combretastatin A-4 prodrug salts that increase the solubility of combretastatin A-4, readily regenerate combretastatin A-4 in vivo under normal physiological conditions, and which produce physiologically tolerable products as a result of the regeneration of combretastatin A-4. | 2009-07-23 |
20090186858 | Synergistic compositions - A synergistic composition comprising a THP salt and a biopenetrant, in which the biopenetrant comprises a polymer of an unsaturated carboxylic acid or a copolymer of an unsaturated carboxylic acid with a sulphonic acid, said polymer or copolymer being terminated by a mono- or diphosphonated unsaturated carboxylic acid group or having such monomers incorporated into the polymer backbone. This composition acts synergistically to enhance the biocidal efficacy of the THP salt against both planktonic (free-swimming) and sessile (attached) bacteria, and also acts synergistically to enhance the efficacy of the THP salt in the dissolution of iron sulphide scale. | 2009-07-23 |
20090186859 | DIAZENIUMDIOLATED NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, COMPOSITIONS THEREOF, AND RELATED METHODS - Disclosed are compounds that release nitric oxide, e.g., a compound of Formula (I) wherein R | 2009-07-23 |
20090186860 | Microbicidal Compositions and their Use - A composition comprising a copper salt of N′-hydroxy-N-cyclohexyldiazenium oxide (CuHDO) and a diluent is useful for combating and/or killing bacteria, mould, yeast and algae in industrial materials and or industrial processes. In a preferred embodiment CuHDO is generated in-situ within the application or medium. The composition may additionally include at least one of certain other biocidal active components. | 2009-07-23 |
20090186861 | Process for Production of Fatty Acids, Fatty Acid Esters and Sterolesters from Soapstock - The invention relates to a process for production of fatty acids directly from soapstock generated in the alkali refining process including the steps of (a) adding a lipase directly to the alkaline soapstock to facilitate hydrolysis of glycerides without prior neutralisation, (b) neutralizing and splitting the soaps with strong acids, and (c) separating the fatty acid phase from the aqueous phase by settling and/or centrifugation. A second embodiment is a process in which the soapstock is first neutralized and split with strong acids, followed by adding a lipase to facilitate glyceride hydrolysis, and separating the fatty acid phase. The fatty acids so obtained can be esterified with C1-C6 alcohols using a lipase that is selective for fatty acids and does not transesterify the sterolesters, and the fatty acid esters and sterolesters are separated by distillation. | 2009-07-23 |
20090186862 | TREATMENT OF CYSTIC FIBROSIS - The present invention discloses a therapeutic target for the treatment of cystic fibrosis. It was found that inhibition of non-lysosomal glucosylceramidase (GBA2) sufficiently restores chloride current in cells from CF patients carrying the common delF508-CFTR mutation. With the catalytic centre (4) of the enzyme positioned on top of the membrane bilayer face particularly potent inhibitors are found in deoxynojirimycin derivatives having a group that is capable of inserting in the membrane bilayer. | 2009-07-23 |
20090186863 | USE OF CHOLEST-4-EN-3-ONE DERIVATIVES FOR OBTAINING A CYTOPROTECTIVE DRUG - The present invention relates to the use of cholest-4-en-3-one derivatives for obtaining a cytoprotective drug, with the exception of a neuroprotective drug. | 2009-07-23 |
20090186864 | RUTHENIUM (II) COMPOUNDS - A ruthenium (II) compound of formula (I): | 2009-07-23 |
20090186865 | Lyophilization Process - An improved process for the production of lyophilized Piperacillin alone or in combination with Tazobactam with improved pH adjustment, by degassing the solution of products to a controlled low carbon dioxide content prior to lyophilization. | 2009-07-23 |
20090186866 | THERAPEUTIC BETA-LACTAMS - Compounds comprising | 2009-07-23 |
20090186867 | Substituted Diketopiperazines As Oxytocin Antagonists - A method of treating or preventing diseases or conditions mediated through the action of oxytocin which comprises administering to a human in need thereof of an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. | 2009-07-23 |
20090186868 | Taxane Compound Having Azetidine Ring Structure - A compound represented by the general formula (1) [X | 2009-07-23 |
20090186869 | Antiviral compounds - The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds. | 2009-07-23 |
20090186870 | Therapeutic Agents - 802 - A compound of formula I | 2009-07-23 |
20090186871 | Tyrosine kinase inhibitors - The present invention relates to compounds that are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases. The compounds of the instant invention possess a core structure that comprises a sulfonyl indole moiety. The present invention is also related to the pharmaceutically acceptable salts, hydrates and stereoisomers of these compounds. | 2009-07-23 |
20090186872 | LOXAPINE ANALOGS AND METHODS OF USE THEREOF - The invention relates to novel compounds and methods of using them for modulating sleep. | 2009-07-23 |
20090186874 | Carboxamide derivative and use thereof - The present invention relates to a compound represented by the formula | 2009-07-23 |
20090186875 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISEASES - Dihydrothienopyrimidines of formula 1 | 2009-07-23 |
20090186876 | Pyridine Analogues II - The present invention relates to certain new pyridin analogues of Formula (I) [Chemical formula should be inserted here. Please see paper copy] Formula (I) to processes for preparing such compounds, to their utility in medicine in general and especially as P2Y | 2009-07-23 |
20090186877 | SUBSTITUTED 1H-BENZIMIDAZOLE-4-CARBOXAMIDES ARE POTENT PARP INHIBITORS - The present invention relates to 1H-benzimidazole-4-carboxamides of formula (I), | 2009-07-23 |
20090186878 | CRYSTALLINE FORMS OF A FARNESYL DIBENZODIAZEPINONE - The present invention relates to crystalline forms of ECO-4601 and the processes for providing them. The invention further relates to pharmaceutical compositions comprising the crystalline forms and to methods of use of the crystalline forms as pharmaceuticals. | 2009-07-23 |
20090186879 | TRICYCLIC COMPOUNDS AND USE THEREOF - There is provided a compound of the formula (I′): | 2009-07-23 |
20090186880 | NOVEL 1,4-DIAZA-BICYCLO[3.2.2]NONANE DERIVATIVES AND THEIR MEDICAL USE - This invention relates to novel 1,4-diaza-bicyclo[3.2.2]nonane derivatives, which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances. | 2009-07-23 |
20090186881 | CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions - The present invention relates to the CGRP-antagonists of general formula I | 2009-07-23 |
20090186882 | CGRP RECEPTOR ANTAGONISTS - The present invention relates to CGRP receptor antagonists, pharmaceutical compositions thereof, and methods therewith for treating CGRP receptor-mediated diseases and conditions. | 2009-07-23 |
20090186883 | Stable Aqueous Suspension - An aqueous pharmaceutical suspension comprising: (i) at least one non-steroidal anti-inflammatory drug; (ii) an aqueous buffer system; (iii) xanthan gum; (iv) polyvinyl pyrrolidone; and (v) glycerol wherein the suspension is free from pregelatinised starch, amino polycarboxylic acid, microcrystalline cellulose, hydroxypropylmethyl cellulose, polyoxyethylene sorbitan monooleate, silicon dioxide and taste modifying agents selected from the group consisting of bulk sweeteners, intense sweeteners, flavouring agents and mixtures thereof. | 2009-07-23 |
20090186884 | Diaminopropanol Renin Inhibitors - Described are diaminopropanols of which are orally active and bind to renin to inhibit its activity. They are useful in the treatment or amelioration of diseases associated with elevated levels of renin activity or in the treatment of aspartic protease mediated disorders. Also described is a method for the use of the diaminopropanols in ameliorating or treating renin related disorders in a subject in need thereof. | 2009-07-23 |
20090186885 | THERAPEUTIC COMPOUNDS - Disclosed herein is a compound according to one of the formulas | 2009-07-23 |
20090186886 | Tricyclic 1,2,4-Triazine Oxides and Compositions for Therapeutic Use in Cancer Treatments - The invention relates to novel tricyclic 1,2,4-triazine-1-oxides and novel tricyclic 1,2,4-triazine-1,4-dioxides of formula I | 2009-07-23 |
20090186887 | NOVEL PYRIMIDOTHIENOINDAZOLES - The invention relates to novel pyrimidothienoindazoles of formula (I) | 2009-07-23 |
20090186888 | NOVEL FUSED PYRROLOCARBAZOLES - The present invention relates generally to selected fused pyrrolocarbazoles, including pharmaceutical compositions thereof and methods of treating diseases therewith. The present invention is also directed to intermediates and processes for making these fused pyrrolocarbazoles. | 2009-07-23 |
20090186889 | SPIRO-SUBSTITUTED PYRROLOPYRIMIDINES - The invention provides compounds of formula I or a pharmaceutically acceptable salt or ester thereof formula I | 2009-07-23 |
20090186890 | Pharmaceutical Formulation of Iressa Comprising a Water-Soluble Cellulose Derivative - A pharmaceutical composition comprising 4-(3′-chloro-4′-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline or a pharmaceutically acceptable salt thereof (the Agent) and a water-soluble cellulose ether or an ester of a water-soluble cellulose ether. The water-soluble cellulose ether or ester of a water-soluble cellulose ether present in the composition inhibits the rate of precipitation of the Agent from solution. | 2009-07-23 |
20090186891 | ORGANIC COMPOUNDS - The present invention provides compounds of the following structure; | 2009-07-23 |
20090186892 | METHODS FOR TREATING LUNG CANCERS - The present invention provided methods for treating lung cancers using therapeutic agents for lung cancers comprising erbB receptor inhibitors as active ingredients. Methods for examining the responsiveness of lung cancer patients to erbB receptor inhibitors by using blood amphiregulin (AREG) as an indicator were provided. Furthermore, methods for treating lung cancers in which responsiveness to an erbB receptor inhibitor is determined based on blood AREG concentration, and in which therapeutic agents are selectively administered to patients expected to be responsive, were also provided. Advanced therapeutic effects can be expected by administering an erbB receptor inhibitor to patients predicted to be responsive. The present invention contributes to the improvement of therapeutic effects of gefitinib (Product name: Iressa®) and such on lung cancers. | 2009-07-23 |
20090186893 | IRE-1alpha INHIBITORS - Compounds which directly inhibit IRE-1α activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies. | 2009-07-23 |